Please Wait
Applying Filters...
menu
    • menu
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Emedastine Fumarate

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 87233-62-3, Rapimine, Emedastine fumarate, Kb-2413, Al-3432a, Daren
    Molecular Formula
    C25H34N4O9
    Molecular Weight
    534.6  g/mol
    InChI Key
    FWLKKPKZQYVAFR-LVEZLNDCSA-N
    FDA UNII
    42MB94QOSM
    Emedastine Difumarate is the difumarate salt form of emedastine, a second generation, selective histamine H1 receptor antagonist with anti-allergic activity. Emedastine reversibly and competitively blocks histamine by binding to H1 receptors, thus blocking its downstream activity. As a result, this agent interferes with mediator release from mast cells either by inhibiting calcium ion influx across mast cell/basophil plasma membrane or by inhibiting intracellular calcium ion release within the cells. In addition, emedastine may also inhibit the late-phase allergic reaction mediated through leukotrienes or prostaglandins, or by producing an anti-platelet activating factor effect. Upon ocular administration, emedastine causes a dose-dependent inhibition of histamine-stimulated vascular permeability in the conjunctiva. Emedastine does not affect adrenergic, dopamine, or serotonin receptors.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (E)-but-2-enedioic acid;1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole
    2.1.2 InChI
    InChI=1S/C17H26N4O.2C4H4O4/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20;2*5-3(6)1-2-4(7)8/h4-5,7-8H,3,6,9-14H2,1-2H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1+
    2.1.3 InChI Key
    FWLKKPKZQYVAFR-LVEZLNDCSA-N
    2.1.4 Canonical SMILES
    CCOCCN1C2=CC=CC=C2N=C1N3CCCN(CC3)C.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O
    2.1.5 Isomeric SMILES
    CCOCCN1C(=NC2=CC=CC=C12)N3CCN(CCC3)C.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    42MB94QOSM
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole Difumarate

    2. Emadine

    3. Emedastine

    4. Kb 2413

    5. Kb-2413

    6. Kg 2413

    7. Kg-2413

    2.3.2 Depositor-Supplied Synonyms

    1. 87233-62-3

    2. Rapimine

    3. Emedastine Fumarate

    4. Kb-2413

    5. Al-3432a

    6. Daren

    7. 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole Difumarate

    8. Kg-2413

    9. Dsstox_cid_26911

    10. 42mb94qosm

    11. Emedastine (difumarate)

    12. Ly-188695

    13. 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1h-benzo[d]imidazole Difumarate

    14. Ly188695

    15. Emadine (tn)

    16. Dsstox_rid_82009

    17. Dsstox_gsid_46911

    18. (e)-but-2-enedioic Acid;1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole

    19. 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1h-1,4-diazepin-1-yl)benzimidazole Fumarate (1:2)

    20. 1h-benzimidazole, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1h-1,4-diazepin-1-yl)-, (e)-2-butenedioate (1:2)

    21. Cas-87233-62-3

    22. 1-(2-ethoxyethyl)-2-(4-methylhexahydro-1h-1,4-diazepin-1-yl)benzimidazole Fumarate (1:2)

    23. Ncgc00181341-01

    24. Unii-42mb94qosm

    25. Remicut

    26. Emedastine Difumarate [usan]

    27. Al 3432a

    28. Mfcd00923844

    29. Daren (tn)

    30. Emedastine Difumarate [usan:usp:jan]

    31. Kb 2413

    32. Emedastinefumarate

    33. Ly 188695

    34. Schembl41384

    35. Schembl41386

    36. Chembl2103739

    37. Dtxsid2046911

    38. C25h34n4o9

    39. Hms3713h04

    40. Hms3886e14

    41. Emedastine Difumarate (jp17/usp)

    42. Emedastine Difumarate [jan]

    43. Emedastine Fumarate [mart.]

    44. Ex-a3661

    45. Hy-b2178

    46. Tox21_112800

    47. Ac-391

    48. Emedastine Difumarate [vandf]

    49. Emedastine Fumarate [who-dd]

    50. S5647

    51. Emedastine Difumarate [usp-rs]

    52. Tox21_112800_1

    53. Ccg-220591

    54. Ncgc00181341-02

    55. As-57174

    56. Benzimidazole, 1-(2-ethoxyethyl)-2-(4-methylhexahydro-1h-1,4-diazepin-1-yl)-, Fumarate (1:2)

    57. Emedastine Difumarate [orange Book]

    58. Emedastine Difumarate [ep Monograph]

    59. Emedastine Difumarate [usp Impurity]

    60. Cs-0021561

    61. E0936

    62. Emedastine Difumarate [usp Monograph]

    63. D02249

    64. T73020

    65. Sr-01000872706

    66. Sr-01000872706-1

    67. Bis((2e)-but-2-enedioic Acid); 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1h-1,3-benzodiazole

    2.4 Create Date
    2005-10-11
    3 Chemical and Physical Properties
    Molecular Weight 534.6 g/mol
    Molecular Formula C25H34N4O9
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count12
    Rotatable Bond Count9
    Exact Mass534.23257867 g/mol
    Monoisotopic Mass534.23257867 g/mol
    Topological Polar Surface Area183 Ų
    Heavy Atom Count38
    Formal Charge0
    Complexity460
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count2
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count3
    4 Drug and Medication Information
    4.1 Drug Indication

    Symptomatic treatment of seasonal allergic conjunctivitis.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Anti-Allergic Agents

    Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)

    Histamine H1 Antagonists

    Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)

    5.2 ATC Code

    S01GX06